European Society of Cardiology


Home
About the ESC
Membership
Communities
Congresses
Education
Guidelines & Surveys
Journals
Initiatives
Welcome to the European Society of Cardiology. Our mission: to reduce the burden of cardiovascular disease in Europe
 

Session Details

Hot Line I: Late Breaking Trials on Prevention to Heart Failure
26 Aug 11:00 - 12:30 Unknown Hot Line, Webcast Munich - Central Village
Chairpersons: Michel KOMAJDA (Paris, FR), Gordon F TOMASELLI (Baltimore, US)

Presentations list

Time
 
FP Nr
 
Title
 
Speakers
 
Related documents
11:00395PURE: Patterns of risk factor prevalence for CVD globally by urbanization, gender, and economic status of countries and individuals: The Prospective Urban Rural Epidemiologic (PURE) Study of 153,996 people from 628 communities in 17 countriesSalim YUSUF (Hamilton, CA)
11:10396Discussant: PURE: Patterns of risk factor prevalence for CVD globally by urbanization, gender, and economic status of countries and individuals: The Prospective Urban Rural Epidemiologic (PURE) Study of 153,996 people from 628 communities in 17 countriesDavid Allan WOOD (London, GB)
11:15397DeFACTO: Determination of Fractional Flow Reserve by Anatomic Computed Tomographic AngiographyJames MIN (Los Angeles, US)
11:25398Discussant: DeFACTO: Determination of Fractional Flow Reserve by Anatomic Computed Tomographic AngiographyJean-Pierre BASSAND (Thise, FR)
11:30399ALTITUDE: ALiskiren Trial In Type 2 Diabetes Using cardio-renal Endpoints Hans Henrik PARVING (Copenhagen, DK)
11:40400Discussant: ALTITUDE: ALiskiren Trial In Type 2 Diabetes Using cardio-renal Endpoints Johannes MANN (Munchen, DE)
11:45401TRILOGY-ACS: Prasugrel versus clopidodrel for patients with Unstable Angina/NSTEMI who are medically managed without revascularization Matthew ROE (Durham, US)
11:55402Discussant: TRILOGY-ACS: Prasugrel versus clopidodrel for patients with Unstable Angina/NSTEMI who are medically managed without revascularizationRaffaele DE CATERINA (Chieti, IT)
12:00403PARAMOUNT: Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Patients with Heart Failure and Preserved Ejection Fraction: Primary Results from the PARAMOUNT StudyScott SOLOMON (Boston, US)
12:10404Discussant: PARAMOUNT: Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Patients with Heart Failure and Preserved Ejection Fraction: Primary Results from the PARAMOUNT StudyPiotr PONIKOWSKI (Wroclaw, PL)
12:15405Aldo-DHF: Aldosterone Receptor Blockade in Diastolic Heart Failure Burkert Mathias PIESKE (Graz, AT)
12:25406Discussant: Aldo-DHF: Aldosterone Receptor Blockade in Diastolic Heart Failure John CLELAND (Kingston Upon Hull, GB)